Biodesix Inc
BDSX
Get informed when a big investor buys or sells
+ FollowMarket Cap$174.36M
Close$
Share Statistics
| Market cap | $174.36 Million |
|---|---|
| Enterprise Value | $220.63 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.67 |
| Beta | 0.52 |
| Outstanding Shares | 9,656,000 |
Return
| Return on Equity | -349.95% |
|---|---|
| Return on Assets | -33.77% |
| Return on Invested Capital | -32.80% |
Valuation & Multiples
| P/E Ratio | -5.28 |
|---|---|
| PEG | 17.7 |
| Price to Sales | 2.35 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.3 |
| Enterprise Value to EBIT | -8.39 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.33 |
| Debt to Equity | 7.87 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$-1.10
Average shareholder expectationRevenue Estimate
$23.19 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.86
Average shareholder expectationRevenue Estimate
$25.93 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 14,800▲ 18.40% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 47.88%▲ 29.98% |
|---|---|
| Total Invested | $52.42M▲ 474.30% |
| Investors Holding | 41▲ 15.00% |
ESG Score
No data
About Biodesix Inc
200 employeesBiodesix, Inc. operates as a biotechnology company. The Company offers non-small cell lung cancer pretreatment serum tests and laboratory testing. Biodesix provides diagnostic tools and equipment for blood and tissue analysis in the United States.